Á. Artal

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial

Rafael Rosell, Enric Carcereny, Radj Gervais et al. · The Lancet Oncology · 2012 · 5.5K citations · Full text

Oncology, Standard Chemotherapy, Randomised Phase 3 +8

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

Louis Fehrenbacher, Alexander I. Spira, Marcus Ballinger et al. · The Lancet · 2016 · 2.8K citations

Non-small-cell Lung Cancer, Medicine, Metronomic Therapy +9

Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB–IIIA non-small-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial

Jean‐Yves Douillard, Rafael Rosell, Mario De Lena et al. · The Lancet Oncology · 2006 · 1.6K citations

Surgical Oncology, Cisplatin Versus Observation, Medicine +10

Randomized Phase III Study of Gemcitabine-Cisplatin Versus Etoposide-Cisplatin in the Treatment of Locally Advanced or Metastatic Non–Small-Cell Lung Cancer

Felipe Cardenal, M.P. López-Cabrerizo, Antonio Antón et al. · Journal of Clinical Oncology · 1999 · 476 citations

Ribonucleotide Reductase Messenger RNA Expression and Survival in Gemcitabine/Cisplatin-Treated Advanced Non-Small Cell Lung Cancer Patients

Rafael Rosell, Kathleen D. Danenberg, V. Alberola et al. · Clinical Cancer Research · 2004 · 358 citations · Full text